Vincerx Pharma Analyst Ratings
Vincerx Pharma Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/07/2023 | 614.29% | Cantor Fitzgerald | → $5 | Reiterates | Overweight → Overweight |
| 11/17/2022 | 328.57% | Chardan Capital | $4 → $3 | Maintains | Buy |
| 08/12/2022 | 614.29% | SVB Leerink | $6 → $5 | Maintains | Outperform |
| 06/08/2022 | 1042.86% | Cantor Fitzgerald | $22 → $8 | Maintains | Overweight |
| 06/07/2022 | 757.14% | B. Riley Securities | $12 → $6 | Maintains | Buy |
| 06/07/2022 | 471.43% | Chardan Capital | $11 → $4 | Maintains | Buy |
| 06/07/2022 | 757.14% | SVB Leerink | $19 → $6 | Maintains | Outperform |
| 05/13/2022 | 1471.43% | Chardan Capital | $14 → $11 | Maintains | Buy |
| 05/13/2022 | 2614.29% | SVB Leerink | $20 → $19 | Maintains | Outperform |
| 03/30/2022 | 2757.14% | SVB Leerink | $24 → $20 | Maintains | Outperform |
| 03/30/2022 | 3900% | HC Wainwright & Co. | $25 → $28 | Maintains | Buy |
| 01/14/2022 | 3471.43% | HC Wainwright & Co. | → $25 | Initiates Coverage On | → Buy |
| 12/23/2021 | 3471.43% | Cantor Fitzgerald | → $25 | Initiates Coverage On | → Overweight |
| 11/01/2021 | 3328.57% | SVB Leerink | → $24 | Initiates Coverage On | → Outperform |
| 09/13/2021 | 4185.71% | Laidlaw & Co. | → $30 | Initiates Coverage On | → Buy |
| 08/25/2021 | 3614.29% | B. Riley Securities | → $26 | Initiates Coverage On | → Buy |
| 08/13/2021 | 4185.71% | Chardan Capital | $33 → $30 | Maintains | Buy |
| 01/06/2021 | 4614.29% | Chardan Capital | → $33 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析師事務所 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 09/07/2023 | 614.29% | 坎託·菲茨傑拉德 | → 5 美元 | 重申 | 超重 → 超重 |
| 11/17/2022 | 328.57% | 查丹資本 | 4 美元 → 3 美元 | 維護 | 購買 |
| 2022 年 12 月 8 日 | 614.29% | SVB Leerink | 6 美元 → 5 美元 | 維護 | 跑贏大盤 |
| 06/08/2022 | 1042.86% | 坎託·菲茨傑拉德 | 22 美元 → 8 美元 | 維護 | 超重 |
| 2022 年 7 月 6 日 | 757.14% | B. 萊利證券 | 12 美元 → 6 美元 | 維護 | 購買 |
| 2022 年 7 月 6 日 | 471.43% | 查丹資本 | 11 美元 → 4 美元 | 維護 | 購買 |
| 2022 年 7 月 6 日 | 757.14% | SVB Leerink | 19 美元 → 6 美元 | 維護 | 跑贏大盤 |
| 05/13/2022 | 1471.43% | 查丹資本 | 14 美元 → 11 美元 | 維護 | 購買 |
| 05/13/2022 | 2614.29% | SVB Leerink | 20 美元 → 19 美元 | 維護 | 跑贏大盤 |
| 03/30/2022 | 2757.14% | SVB Leerink | 24 美元 → 20 美元 | 維護 | 跑贏大盤 |
| 03/30/2022 | 3900% | HC Wainwright & Co. | 25 美元 → 28 美元 | 維護 | 購買 |
| 2022 年 1 月 14 日 | 3471.43% | HC Wainwright & Co. | → 25 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 12/23/2021 | 3471.43% | 坎託·菲茨傑拉德 | → 25 美元 | 啓動覆蓋範圍開啓 | → 超重 |
| 11/01/2021 | 3328.57% | SVB Leerink | → 24 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 09/13/2021 | 4185.71% | Laidlaw & Co. | → 30 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2021 年 8 月 25 日 | 3614.29% | B. 萊利證券 | → 26 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 08/13/2021 | 4185.71% | 查丹資本 | 33 美元 → 30 美元 | 維護 | 購買 |
| 01/06/2021 | 4614.29% | 查丹資本 | → 33 美元 | 啓動覆蓋範圍開啓 | → 購買 |
What is the target price for Vincerx Pharma (VINC)?
Vincerx Pharma（VINC）的目標價格是多少？
The latest price target for Vincerx Pharma (NASDAQ: VINC) was reported by Cantor Fitzgerald on September 7, 2023. The analyst firm set a price target for $5.00 expecting VINC to rise to within 12 months (a possible 614.29% upside). 2 analyst firms have reported ratings in the last year.
坎託·菲茨傑拉德於2023年9月7日公佈了Vincerx Pharma（納斯達克股票代碼：VINC）的最新目標股價。該分析公司將目標股價設定爲5.00美元，預計VINC將在12個月內上漲至5美元（可能上漲614.29％）。去年有兩家分析公司公佈了評級。
What is the most recent analyst rating for Vincerx Pharma (VINC)?
Vincerx Pharma（VINC）的最新分析師評級是多少？
The latest analyst rating for Vincerx Pharma (NASDAQ: VINC) was provided by Cantor Fitzgerald, and Vincerx Pharma reiterated their overweight rating.
Vincerx Pharma（納斯達克股票代碼：VINC）的最新分析師評級由坎託·菲茨傑拉德提供，Vincerx Pharma重申了他們的增持評級。
When is the next analyst rating going to be posted or updated for Vincerx Pharma (VINC)?
Vincerx Pharma（VINC）的下一個分析師評級何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Vincerx Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Vincerx Pharma was filed on September 7, 2023 so you should expect the next rating to be made available sometime around September 7, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Vincerx Pharma的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應獲得4個評級。Vincerx Pharma的最後一次評級是在2023年9月7日公佈的，因此您應該預計下一個評級將在2024年9月7日左右公佈。
Is the Analyst Rating Vincerx Pharma (VINC) correct?
分析師評級Vincerx Pharma（VINC）是否正確？
While ratings are subjective and will change, the latest Vincerx Pharma (VINC) rating was a reiterated with a price target of $0.00 to $5.00. The current price Vincerx Pharma (VINC) is trading at is $0.70, which is within the analyst's predicted range.
儘管評級是主觀的，並將發生變化，但最新的Vincerx Pharma（VINC）評級得到了重申，目標股價爲0.00美元至5.00美元。Vincerx Pharma（VINC）目前的交易價格爲0.70美元，在分析師的預測區間內。
譯文內容由第三人軟體翻譯。